TLDR
- ARK Invest bought 781,519 Joby Aviation shares for $10.4 million after the stock plunged 16.7% on January 29, 2026
- The air taxi company plans to raise $1 billion through stock sales and convertible notes, sparking dilution worries among investors
- ARK dumped 31,668 Teradyne shares for $7.9 million as the semiconductor stock peaked at $253.61 per share
- The investment firm added 127,184 CRISPR Therapeutics shares worth $6.8 million, extending its biotech buying streak
- ARK trimmed Veracyte and Illumina positions while adjusting smaller holdings in Beam Therapeutics and Kratos Defense
ARK Invest made several portfolio adjustments on January 29, 2026, according to daily trading disclosures. The investment firm led by Cathie Wood focused on electric aviation and biotech sectors while reducing semiconductor exposure.
The biggest transaction involved Joby Aviation, with ARK purchasing 781,519 shares totaling $10.4 million. The buy was split between ARK Autonomous Technology & Robotics ETF and ARK Space Exploration & Innovation ETF.
Joby Aviation stock dropped 16.7% during Thursday’s trading session. The sharp decline followed news that the company intends to raise $1 billion in fresh capital. The air taxi developer plans to issue common stock and convertible senior notes with a 2032 maturity date.
Shareholders responded negatively to the funding announcement. Concerns centered on potential ownership dilution from the new share issuance. ARK viewed the price drop as an entry point to build its position in the flying taxi sector.
Biotech Buying Continues
ARK Invest increased its gene-editing exposure by purchasing 127,184 CRISPR Therapeutics shares. The $6.8 million investment was spread across ARKK and ARKG ETFs.
This marks another addition to ARK’s growing CRISPR position. The firm has been buying shares consistently over recent trading days. CRISPR Therapeutics stock saw a modest decline alongside broader market weakness on Thursday.
Teradyne Exit Near 52-Week High
ARK sold its Teradyne holdings at favorable prices, offloading 31,668 shares for $7.9 million. The trades went through ARKQ and ARKX ETFs. Teradyne reached an intraday high of $253.61 during the session.
The stock rallied following a joint venture announcement. Teradyne and MultiLane revealed plans to create MultiLane Test Products, a new company focused on high-speed data testing for AI data centers.
MultiLane will contribute testing and measurement technology to the partnership. The company keeps its interconnect products and data center testing units. Teradyne secures majority control of the newly formed venture.
Regulatory approval is pending for the transaction. Both parties expect completion during the first half of 2026. ARK has been steadily reducing its Teradyne stake throughout the week.
Other Portfolio Adjustments
ARK liquidated 31,463 Veracyte shares through ARKK ETF, collecting $1.2 million. The firm cut its Illumina stake by 35,897 shares across ARKK and ARKG funds. Both moves align with ARK’s ongoing reduction in these biotech names.
Additional trades included acquiring 29,413 Beam Therapeutics shares. ARK also offloaded 261 Kratos Defense and Security Solutions shares. Market analysts rate Teradyne and CRISPR Therapeutics as “Moderate Buy” recommendations, while Joby Aviation holds a “Hold” rating despite projected 41% upside potential over the next year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
